Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 3/20 | 0.39 |
| ▸ | CCR3 | P51677 | 3/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.38 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4504147 | 0.92 | HSD11B1 (0.50) | HSD11B1FFAR1MCL1HRH1CCR3 | |
| SCHEMBL13674464 | 0.90 | HSD11B1 (0.44) | HSD11B1FFAR1PTGDR2SIGMAR1PTGDR | |
| SCHEMBL4526129 | 0.88 | SIGMAR1 (0.42) | HSD11B1SIGMAR1TSHRHSD17B10 | |
| SCHEMBL4525800 | 0.88 | HSD11B1 (0.47) | HSD11B1FFAR1HRH1 | |
| SCHEMBL4509399 | 0.87 | MCL1 (0.39) | HSD11B1FFAR1MCL1HRH1CCR3 | |
| SCHEMBL4516252 | 0.87 | HSD11B1 (0.55) | HSD11B1FFAR1 | |
| SCHEMBL4521181 | 0.87 | HSD11B1 (0.46) | HSD11B1FFAR1 | |
| SCHEMBL4513450 | 0.86 | HSD11B1 (0.48) | HSD11B1 | |
| SCHEMBL4517793 | 0.86 | HSD11B1 (0.52) | HSD11B1TSHR | |
| SCHEMBL4519338 | 0.86 | HSD11B1 (0.60) | HSD11B1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1864971-A1 | PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885FFAR1 326/4885MCL1 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.